

DAFTAR PUSTAKA

- Agrawal, A.K., Pielka, E., Lipinski, A., Jelen, M., Kielan, W., dan Agrawal, S. Clinical validation of nuclear factor kappa B expression in invasive breast cancer. *Tumor Biology*, 2018: 1–10.
- Alaaragyl, B.A., Altemimi, I., et al. Comparison of molecular subtypes between primary breast cancer and its metastatic auxiliary lymph node (s), *Ann Trop Med & Public Health*. 2020. 23(S13A): SP231339.
- American Cancer Society. *Cancer facts and Figure*. Atlanta American Cancer Society. 1994.
- American Joint Committee on Cancer. Breast. In : Greene FL, Compton CC, Fritz AG, Shah JP, Winchester JP, editors. *AJCC Cancer Staging Atlas*. Springer, 2006; p: 217-33.
- Andrea, O., & Sankar, G. The NF- κ B family of transcription factors and its regulation. *Cold Spring Harbor Laboratory Pre.s*, 2009:1;1-14.
- Ariga, A., Namekawa, J., Matsumoto, N., Inoue, J. & Umezawa, K. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. *J Biol, Chem*. 2002.; 277, 24625-30.
- Avagliano, A., Ruocco, M.R., Aliotta, F., Belviso, I., Accurso, A., Masone, S., Montagnani, S., dan Arcucci, A. Mitochondrial Flexibility of Breast Cancers: A Growth Advantage and a Therapeutic Opportunity. *Cells* 2019, 8, 401.
- Bardia, et all. Recreational Physical Activity and Risk of Post Menopause Breast Cancer Based on Hormon Receptor Status. *Arch Intern Med*. 2006. Dec.11-25. 166(22); p:2478-83.
- Barisic, S., Strozky, E., Peters, N. & Kulms, D. Identification of PP2A as a crucial regulator of the NF-kappaB into a pro-apoptotic factor. *Cell Death Differ*. 2008. (15): (11). 1681-90.
- Barr, M. P., Gray, S. G., Haffmann, A. C., Hilger, R. A., Thomale, J. & Flaherty, J. Generation and characterisation of cisplatin resistant non small cell lung cancer cell lines displaying a stem like signature. *PloS One*. 2013. 8:e 54193.
- Beral V, Bull D, Pirie K, Reeves G. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. *Lancet Oncol* 2012; 13: 1141–51.
- Boedina S. Angiogenesis dan Metastasis. In : Ilmu Dasar Onkologi, Fakultas Kedokteran Universitas Indonesia, 2011; p: 220-53.

- Bonizzi, G. & Karin, M. The two NF- κ B activation pathway and their role in innate and adaptive immunity. *Trends Immunol.* 2004: 25, 280-8.
- Bottero, V., Busuttil, V., Loubat, A., Magne, N., Fischel, J. L., Milano, G. & Peyron, J. F. Activation of nuclear factor κ B through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: A brake to apoptosis in HeLa human carcinoma cells. *Cancer Research.* 2001: 61, 7785-91.
- Bucur, O., Ray, S., Bucur, M. C. & Almasan, A. APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. *Frontiers in Bioscience.* 2006: 11, 1549-68.
- Byrne GJ, Mc Dowell G, Agarawal R, Sinha G, Kumar S, Bundred NJ. Serum Vascular Endothelial Growth Factor in Breast Cancer. *Anticancer Research.* 2007; 27; p: 3481-88.
- Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Carter, W. B., Edge, S. B., Erban, J. K., Farrar, W. B., Goldstein, L. J. & Gradishar, W. J. 2009. Breast cancer. *Journal of the National Comprehensive Cancer Network*, 7, 122-92.
- Cheang MCU, Chia SK, Voduc D, et al (2009). Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *J Natl Cancer Inst*, 101, 736–50.
- Chen. L. F. & Greene. W. C. Targeting of RelA by multiple protein kinases induced by distinct stimuli. *Nature Reviews Molecular Cell Biology.* 2004; 5, 392-401.
- Cogswell, P. C., Guttridge, D. C., Funkhouser, W. K. And Baldwin, A. S. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B alternative pathway (p100/p52) and for Bcl-3. *Oncogen.* 2000; 19: (9),1123-31.
- Connolly, R. M. & Stearns, V. Current approaches for neoadjuvant chemotherapy in breast cancer. *European journal of pharmacology*, 2013; 717, 58-66.
- Crowley, J. E., Treml, L. S., Stadanlick, J. E., Carpenter, E. & Cancro, M. P. Homeostatic niche specification among naive and activated B cells: a growing role for the BlyS family of receptors and ligands. *Semin, Immunol.* 2005. 17, 192-9.
- De Benedetti, A., & Graff, J. R. eIF-4E expression and its role in malignancies and metastases. *Oncogene.* 2004. 23, 3189-99.
- Denkert, C., Sinn, B. V., Issa, Y., Muller, B. M., Maisch, A., Untch, M., Von Minckwitz, G. & Loibl, S. Prediction of response to neoadjuvant chemotherapy: new biomarker approaches and concepts. *Breast Care.* 2011. 6, 265-72.

- Dhanushkodi, M., Sridevi, V., Shanta, V., Rama, R., Swaminathan, R., Selvaluxmy, G., dan Ganesan, T.S. Locally Advanced Breast Cancer (LABC): Real-World Outcome of Patients From Cancer Institute, Chennai. *JCO Global Oncol.* 2021; 7:767-781.
- Dowlathshahi Kambiz. Abnormal mammography; in *Surgical Oncology an Algorithmic Approach*, New York: Springer-Verlag inc; 2003; p: 188-95.
- Duffy, M. J. Tumor markers in clinical practice: a review focusing on common solid cancers. *Med Princ Pract.* 2013. 22, 4-11.
- El Saghir. Breast Cancer In Arab Countries. *PAJO.* 2009. Apr.2(2); p:14-5.
- Elesawy, B.H., Abd, A., Shawky, A.E., et al. Immunohistochemistry-based subtyping of breast carcinoma in Egyptian women: A clinicopathologic study on 125 patients. *Ann Diagn Pathol*, 2014. 18, 21–6
- Ellis IO. Invasif Breast Carsinoma. *Tumours of Breast. Pathology and Genetics of Tumours of The Breast and Female Genital Organs. WHO Classification of Tumours. Chapter 1.* Tavassoli. 2003; p: 10-30.
- Engstrom, M., Opdhal, S., Hagen, A., Romundstad, P., Akslen, L., Haugen, O., Vatten, L. & Bofin, A. Molecular subtypes, histopatological grade and survival in a historic cohort of breast cancer patients. *Breast cancer research and treatment*, 2013. 140, 463-73.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer.* 2015; 136: E359-E386.
- Firdaus VR, Asri A, Khambri D, Harahap WA. Hubungan grading histopatologi dan infiltrasi limfovaskular dengan sub tipe molekuler pada kanker payudara invasif di Bagian Bedah RSUP. Dr. M. Djamil Padang. *J Kesehat Andalas.* 2016;5(1):165–72.
- Frasor J; Weaver A; Pradhan M; Dai Y; Miller LD; Lin CY; Stanculescu A, Positive cross-talk between estrogen receptor and NF-kappa B in breast cancer. *Cancer Res*, 2009, 69 (23), 8918-8925.
- Frasor, J., El-Shennawy, L., Stender, J.D., dan Kastrati, I. NFκB Affects Estrogen Receptor Expression and Activity in Breast Cancer through Multiple Mechanisms. *Mol Cell Endocrinol.* 2015 December 15; 418(0 3): 235–239.
- Furqan M, Pohan PU. Relationship of Histopathology Grading with Molecular Subtypes of Breast Cancer Patients in Haji Adam Malik General Hospital 2016-2018. *SCRIPTA SCORE Scientific Medical Journal*, 2020: 2(1).

- Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in Primary Breast Cancer. *Breast Cancer Research and Treatment*. Vol 22(3), 1992; p: 207-19.
- Gao JJ, and Swain SM. Luminal A Breast Cancer and Molecular Assays:
- Garrido-Castro, A.C., Lin, N.U., dan Polyak, K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. *Cancer Discov*. 2019; 9(2): 176–198.
- Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M. Prognostic Significance of Vascular Endothelial Growth Factor Protein in Node-negative Breast Carcinoma. *J. Natl, Cancer Inst*. 1997; 89; p: 139-47.
- Gershtein ES, Scherbakov AM, Platova AM, *et al*. The expression and DNA-binding activity of NF- κ B nuclear transcription factor in the tumors of patients with breast cancer. *Bull Exp Biol Med* 2010; 7: 80–4.
- Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thu B. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, 2011. *Ann Oncol*, 22, 1736–47.
- Grandage, V. L., Gale, R. E., Linch, C. & Khwaja, A. P13-kinase/ Akt is constitutively active in primary acute myeloid leukemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. *Leukimi*. 2005. a 19, 586-94.
- Hashmi AA, Mahboob R, Khan SM, Irfan M, Nisar M, Iftikhar N, Siddiqui M, Faridi N, Khan A dan Edhi MM. Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers. *BMC Res Notes* 2018; 11:574.
- Heer K, Kumar H, Read JR. Serum Vascular Endothelial Growth Factor in Breast Cancer : Its Relation with Cancer Type and Estrogen Receptor Status. *Clin Cancer Res*. 2001; 7; p: 3491-4.
- Hinz, M. & Scheidereit, C. 2014. The IkappaB kinase complex in NF-kappaB regulation and beyond. *EMBO Rep*. 15: (1). 46-81.
- Hsiao YH; Chou MC; Fowler C; Mason JT; Man YG, Breast cancer heterogeneity: mechanisms, proofs, and implications. *J.Cancer*, 2010, 1, 6–13.
- Huang B; Yang XD; Lamb A; Chen LF Posttranslational modifications of NF-kappa B: another layer of regulation for NF-kappaB signaling pathway. *Cell Signal*, 2010, 22 (9), 1282–1290.

- Indra, Manginstar C, Islam AA, Sampepajung D, Hamdani W, Bukhari A, Syamsu SA, Prihantono, Smaradania N, Faruk M. The relationship between NFkB, HER2, ER expression and anthracycline -based neoadjuvant chemotherapy response in local advanced stadium breast cancer: A cohort study in Eastern Indonesia. *Annals of Medicine and Surgery* 2021; 63(2021): 102164.
- Ivshina AV, George J, Senko O et al. Genetic Reclassification of Histologic Grade Delineates new Clinical Subtypes of Breast Cancer. *Molecular Biology. Pathobiology and Genetics*. Departement of Pathology Sweden. 2006.
- Jana D, Das S, Sarkar DK, Mandal S, Maji A, Mukhopadhyay M. Role of Nuclear Factor- κ B in female Breast Cancer: A Study in Indian Patients. *Asian Pacific Journal of Cancer Prevention*, 2012; 13(2012): 5511-5515.
- Jones RL, Rojo F, A'Hern R, Villena N, Salter J, Corominas JM, Servitja S, Smith IE, Rovira A, Reis-Filho JS, Dowsett M, Albanell J. Nuclear NF-kappaB/p65 expression and response to neoadjuvant chemotherapy in breast cancer. *J Clin Pathol*. 2011; 64:130–135.
- Jones, R.L., Rojo, F., A'Hern, R., Villena, R., Salter, J., Corominas, J.M., Servitja, S., Smith, I.E., Rovira, A., et al. Nuclear NF-kB/p65 expression and response to neoadjuvant chemotherapy in breast cancer. *J Clin Pathol* 2011;64:130e135.
- Karim, M. & Lin, A. 2002. NF-kappaB at the crossroads of live and death. *Nat Immunol*,3, 221-27.
- Kim, S., Sohn, J., Koo, J.S., Park, S.H., Park, H.S., Park, B.W. Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer. *Oncology* 2010;79:324–330.
- Lainetti, P.F., Leis-Filho, A.F., Laufer-Amorim, R., Battazza, A., dan Fonseca-Alves, C.E. Mechanisms of Resistance to Chemotherapy in Breast Cancer and Possible Targets in Drug Delivery Systems. *Pharmaceutics*. 2020, 12, 1193
- Lapcik, P., Pospisilova, A., Janacova, L., Grell, P., Fabian, P., dan Bouchal, P. How Different Are the Molecular Mechanisms of Nodal and Distant Metastasis in Luminal A Breast Cancer? *Cancers* 2020, 12, 2638.
- Lester SC. *The Breast in Text book of Robbin's Pathologic Basic of Disease*; Chapter 23. 8th Ed. Phil. W.B Saunders Co. 2010; p: 1083-90.
- li, L.I., Jang*, G., Chen, Q, dan Zheng, J.N. Predict Ki67 is a promising molecular target in the diagnosis of cancer (Review). *Molecular medicine reports* 11: 1566-1572, 2015

- Linderholm B, Tavelin B, Grankvist K, Henriksson R. Vascular Endothelial Growth Factor is of High Prognostic value in Node-negative Breast Carcinoma. *J. Clin. Oncol.* 1998; 16; p: 3121-8.
- Liu, Y., Du, F., Chen, W., Yao, M., Lv, K. & Fu, P. 2013. Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin. *Experimental cell research*, 319, 3140-9.
- Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. *Mod Pathol*, 2006. 19, 264–71.
- Maiello MR, De Luca A, Gallo M, D'Alessio G, Normanno N. Signal Transduction Inhibitors in The Treatment of Breast Cancer. In : Giordano A, Normanno N. Editors. *Breast cancer in The Post Genomic Era*. 2009; p: 177-202.
- Martin GS. Normal cells and Cancer cells in : Bishop JM, Weinstein RA, editors. *Molecular Oncology*. New York: Scientific American. 1996; p: 13-40.
- Masood S. Prediction of Recurrence for Advance Breast Cancer. Traditional and Contemporary Pathologic and Molecular Markers. *Surg Oncol Clin N Am*, 1995; Oct.4(4); p: 601-32.
- Mei. Y., Cai, D., Dai, X. Modulating cancer stemness provides luminal a breast cancer cells with HER2 positive-like features. *Journal of Cancer* 2020; 11(5): 1162-1169.
- Montagut C, Tusquest I, Ferrer B, et all. Activation of nuclear factor k B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. *Endocrine-Related Cancer*. 2006; (13); p: 607-16
- Mowla, S.N., Perkins, N.D., Jat, P.S. Friend or foe: emerging role of nuclear factor kappa-light-chain-enhancer of activated B cells in cell senescence. *OncoTargets and Therapy* 2013;6 1221–1229
- National Comprehensive Cancer Network. Breast Cancer. 2008. Online at: www.nccn.org.
- O'Reilly MS, Boehm T, Shing Y, et all. Endostatin : An Endogenous Inhibitor of Angiogenesis and Tumor Growth. *Cell J*, Jan. 1997, 88(2); p: 277-85.
- Obondoa, C., Tannahilla, A al Murri, J. Doughtyb, J. Edwardsa,, D. McMillana Viale G, et al. The Relationship Between Ki-67 Labelling Index, Angiogenesis, Nuclear Factor Kappa B And Survival In Primary Invasive Breast Cancer. *J Natl Cancer Inst*. 2008;100:207-12
- Pacifico, F. & Leonardi, A. 2006. NF-κB in solid tumors. *Biochemical pharmacology*, 72, 1142-52.

- Page, R. & Takimoto, C. Principles of chemotherapy. *Cancer management: a multidisciplinary approach, 5th ed. Melville, NY: PRR, Inc.* 2001; 20-31
- Pavlou. M. P., Diamandis E. P. & Blasutig, I. M. The long journey of cancer biomarkers from the bench to the clinic. *Clin Chem.* 2013. 59, 147-57.
- Perkins, N. D. Integrating cell-signalling pathways with NF- κ B and IKK function. *Nature Publishing Group.* 2007. 8, 49-62.
- Prabudi, Manuaba, I.B.T.W., dan Sudarsa, I.W. Overexpression of nuclear factor kappa B (NF- κ B) protein as a risk factor for anthracyclin chemoresistance in luminal a subtype locally advanced breast cancer (LABC) at Sanglah General Hospital, Bali – Indonesia. *Bali Medical Journal (Bali Med J).* 2020, 9(3): 686-690.
- Prati, R., Minami, C.A., Gornbein, J.A., Debruhl, N., Chung, D., daChang, H.R. Accuracy of Clinical Evaluation of Locally Advanced Breast Cancer in Patients Receiving Neoadjuvant Chemotherapy. *Cancer.* 2009. 15; 115(6): 1194–1202.
- Press, M. F., Sauter, G., Buyse, M., Bernstein, L., Guzman, R., Santiago, A., Villalobos, I. E., Eiermann, W., Pienkowski, T. & Martin, M. 2011. Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy. *Journal of Clinical Oncology*, 29, 859-67.
- Prosnitz LR, Iglehart JD, Winer EP. Breast Cancer. In : Rubin P, editors. *Clinical Oncology, A Multidisciplinary Approach for Physicians and Students*, 8th ed. WB Saunders Co. 2001; p: 267-96.
- Razani, B., Zarnegar, B., Ytterberg, A. J., Shiba, T., Loo, J. A. & Cheng, G. Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKalpha-mediated phosphorylation. *Sci Signal.* 2010. 3: (123). 41.
- Rhodes, A. & Yip, C. Comparison of breast cancer in Indonesia and Malaysia a clinico-pathological study between Dharmas Cancer Centre Jakarta and University Malaya Medical Centre, Kuala Lumpur. *Asian Pacific Journal of Cancer Prevention*, 2011, 12, 2943-46.
- Rosai J. The Breast in Text Book of Ackerman's Surgical Pathology. 9th Ed. ST. Louis: Mosby. 2004; p: 1763-876.
- Rosen P. Invasif Ductal Carcinoma Assesment of Prognosis, Morphologic Prognostic Markers and Tumor Growth Rate. In : Text book of Rosen's Breast Pathology, 3rd Ed. 2009; p: 369-79.

- Sainsburry, Anderson TJ, Morgan DAL. Breast Cancer. *BMJ*, 2000: 321; p: 745-51.
- Salhia B, Tapia C, Ishak EA, Gaber S, Berghuis B, Hussain KH, et al. Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. *BMC Womens Health*. 2011;11(44):1–9.
- Sampepajung D. Kanker Payudara di Indonesia, Masalah dan Penanggulangannya. Naskah Pidato pada Upacara Pengukuhan sebagai Guru Besar Bidang Ilmu Bedah onkologi Fakultas Kedokteran Universitas Hasanuddin, Makassar, 27 Desember 2010.
- Sampepajung D. Pendekatan Biologi Molekuler pada Penderita Kanker Payudara dan Keluarga Seketurunan dengan pelacakan Mutasi Gen BRCA-1 di Makassar. Disertasi Program Pasca Sarjana Universitas Hasanuddin, Makassar, 2003.
- Sarkar, D.K., Jana , D., Patil, P.S., Chaudhari, K.S., Chattopadhyay, B.K., Chikkala, B.R., Mandal, S., dan Chowdhary, P. Role of NF- κ B as a Prognostic Marker in Breast Cancer : A Pilot Study in Indian Patients. *Indian J Surg Oncol*. 2013. 4(3):242–247.
- Sas, L., Lardon, F., Vermeulen, P.B., Hauspy, J., Dam, P.V., Pauwels, P., Dirix, L.Y. dan Laere, S.J.V. The interaction between ER and NF κ B in resistance to endocrine therapy. *Breast Cancer Research* 2012, 14:212.
- Sau A, Cabrita MA, and Pratt MAC. NF- κ B at the Crossroads of Normal Mammary Gland Biology and the Pathogenesis and Prevention of BRCA1-Mutated Breast Cancer. *Cancer Prev Res* 2018; 11(2).
- Schnitt SJ. Traditional and Newer Pathologic Factors. *J Natl Cancer Inst Monogr*, 2001; 30; p: 22-6.
- Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G. Genome regulation by polycomb and trithorax proteins. *Cell*. 2007; 128:735–745.
- Septiawidiyati TR, Auerkari EI. Genotoxin Effect Of Composite Resin. *Indonesian Journal of Legal and Forensic Sciences* 2019; 1(1): 8-18.
- Shapochka, D.O., Zaletok, S.P., Gnidyuk, M.I. Relationship Between Nf-Kb, Er, Pr, Her2/Neu, Ki67, P53 Expression In Human Breast Cancer. *Exp Oncol* 2012 34, 4, 358–363.
- Sidhu SS, Kossiakoff AA. Exploring and Designing Protein Function with Restricted Diversity. *Curr. Opin. Chem. Biol*. 2007; 11; p: 347-54.
- Simplicio-Revoredo, C.M., Pereira², R.O., Melo, M.A., Lopes-Costa, P.V., Tarso, P., Moura-Borges, Sousa, E.B. Expression of Nrf2 and NF- κ B transcription

- factors in breast cancer and breast fibroadenoma: Insights for a new therapeutic approach. *Oncotarget*, 2020, 11(18): 1629-1636.
- Skoog P, Ohlsson M, FernoÈ M, RydeÅn L, Borrebaeck CAK, Wingren C. Tumor tissue protein signatures reflect histological grade of breast cancer. *PLoS ONE*. 2017.12(6): e0179775.
- Smetana K, Lacina L, Szabo P, Dvořánková B, Brož5 P dan Šedo A. Ageing as an Important Risk Factor for Cancer. *Anticancer Research* 2016; 36(2016): 5009-5018.
- Soliman, N.A., Yussif, S.M. Ki-67 as a prognostic marker according to breast cancer molecular subtype. *Cancer Biol Med* 2016.
- Solorzano CC, Ahearne PM, Leach SD. Invasif Breast Cancer. In : Berger DH, Feigh BW, Fuhrman, editors. *The MD Anderson Surgical Oncology Handbook*, 3th ed. Lippincott Williams and Wilkins. 2003; p: 14-28.
- Speth, P., Van Hoesel, O. & Haanen, C. 1988. Clinical pharmacokinetics of doxorubicin. *Clinical pharmacokinetics*, 15, 15-31.
- Sukardja IDG. Etiologi Kanker dalam Onkologi Klinik, Edisi 2, Airlangga University Press, Surabaya. 2000: p: 113-25.
- Surakasula A, Nagarjunapu GC, Raghavaiah KV. A comparative study of pre- and post-menopausal breast cancer: Risk factors, presentation, characteristics and management. *Journal of Research in Pharmacy Practice* 2014; 3(1): 12-18.
- Taghian, A., Meraiver, S.D., Haves, D.F., Vora, S., dan Chen, W. Patient education: Locally advanced and inflammatory breast cancer (Beyond the Basics). *UpToDate*. 2020.
- Tamaki M, Kamio T, Kameoka S, Kojimahara N, Nishikawa T. The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients. *World J Surg Oncol*. 2013;11:1–13. doi: 10.1186/1477-7819 11-293
- Tanaka, K., Babic, I., Nathanson, D., Akhavan, D., Guo, D. & Gini, B. 2011. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. *Cancer Discov*. 1, 524-38.
- Taneja P, Maglic D, Kai F, Zhu S, Kendig RD, Fry EA, Inoue K. Classical and Novel Prognostic Marker for Breast Cancer and Their Clinical Significance. *ClinMed Insight Oncol*. 2010; 4; p: 15-34.
- Thangjam S, Laishram RS, Debnath K. Breast carcinoma in young females below the age of 40 years: A histopathological perspective. *South Asian Journal of Cancer* 2014; 3(2): 97-98.

- Thomas, A., Bucholz., Amit, K & Grag. The nuclear transcription factor kB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. *American Association for Cancer Research*. 2005. 11, 8398-403.
- Tjindarbumi D, Ramli M. Clinicopathological Aspect of Breast Cancer. A Joint Study between Indonesia and Japan. *Med J of Indonesia*. 1995; 4(3):143-8
- Viennois, E., Chen, F. & Merlin, D. NFκB pathway in colitis-associated cancers. *Transl Gastrointest Cancer*. 2013. 2 (1), 21-9.
- Vincent T. De Vita, E. C. Principles Of Cancer Chemotherapy. *In*: Edward Chu, V. T. D. V. (ed.). Physicians cancer chemotherapy drug manual 2008. *Massachusetts: Jones and Bartlett*. 2008. 34-42.
- Vogl G, Bartel H, Dietze O, Hauser-Kronberger C. Her2 is Unlike to be Involved in Disectly Regulating Angiogenesis in Human Breast Cancer. *Appl Immunohistochem Mol Morphol*. 2006; 14(2); p: 138-45
- Wang W, Nag SA, Zhang R. Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy. *Curr Med Chem*. 2015; 22(2): 264–289.
- Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D, Sonenshein GE. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. *Nat Cell Biol*. 2007; 9:470–478.
- Weinberg, R. P53 and apoptosis: Master guadian and executioner. *In* : The Biology of Cancer. *New York, Garland Sc*.101, 2007: 307-356.
- Willet WC, Rockhill B, Hankinson SE, Hunter DJ, Colditz GA. Epidemiology and Non Genetic Causes of Breast Cancer. *In* : Harris JR, Lippman MC, Morrow M, Osborne CK, editors. *Disease of The Breast*. 2nded. Lippincott Williams and Wilkins, Philladelphia. 2000; p: 175-220.
- Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *Arch Pathol Lab Med*, 2014. 138, 241–56.
- Wong, R. S. Y. 2011. Apoptosis and cancer: from pathogenesis to treatment. *J Exp & Clin Cancer Res* 2011, 30: 87. Diunduh dari <http://www.jeccr.com/content/30/1/87>.
- Yersal O dan Baruta S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. *World J Clin Oncol* 2014; 10; 5(3): 412-424.

- Zhang M, Liu H, Teng X, et al. The differences in CXCR4 protein expression are significant for the five molecular subtypes of breast cancer. *Ultrastruct Pathol*, 2012. 36, 381–6.
- Zhang, B., Cao, X., Chen, J., Chen, J., Fu, L., Hu, X., Jiang, Z., Li, H., Liao, N., Liu, D., Tao, O., Shao, Z., Sun, Q., Wang, S., Wang, Y., Xu, B., Zhang J., Guidelines on the diagnosis and treatment of breast cancer (2011 edition). *Gland Surgery* 2012;1(1):39-61.
- Zhao J, Yan F, Ju H, Tang J, Qin J. Correlation between Serum Vascular Endothelial Growth Factor and Endostatin Level in Patients with Breast Cancer. *J CanLet*. 2004, 204: 87-95.
- Zhou, Y., Eppenbergs-Castori, S., Eppenbergs, U. & Benz, C. C. The NF-KB pathway and endocrine resistant Breast cancer. *Endocrine –Related Cancer*, 2005. 37-46.
- Zinzalla, V., Straca, D., Oppliger, W., & Hall, M. N. Activation of mTORC2 by association with the ribosome. *Cell*. 2011; 144, 757-68.



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN



KOMITE ETIK PENELITIAN KESEHATAN

RSPTN UNIVERSITAS HASANUDDIN

RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR

Sekretariat : Lantai 2 Gedung Laboratorium Terpadu

JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.

Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411

5780103, Fax : 0411-581431

LAMPIRAN 5

SURAT PERSETUJUAN

Yang bertandatangan di bawah ini :

Nama : Dr. dr. Indra , Sp.B(K)Onk
NIP : 197005052000121001
Jabatan : Pembimbing

Sebagai atasan langsung dari :

Nama : dr.Martua Arpollos
NIM : C045 181 007
Pekerjaan : Peserta PPDS (Residen) Departement Bedah FK UNHAS

Menyatakan menyetujui bila yang bersangkutan melakukan penelitian dengan judul :

**Korelasi Ekspresi NF-KB terhadap Luminal dan Non Luminal Subtipe Molekuler
pada kasus Kanker Payudara Stadium Lanjut**

Makassar, Maret 2022

Dr. dr. Indra , Sp.B(K)Onk
NIP : 197005052000121001



REKOMENDASI PERSETUJUAN ETIK

Nomor : 198/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 27 April 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22040164	No Sponsor Protokol	
Peneliti Utama	dr. Martua Arpollos	Sponsor	
Judul Peneliti	Korelasi Ekspresi NF-KB terhadap Luminal dan Non Luminal Subtipe Molekuler pada kasus Kanker Payudara Stadium Lanjut		
No Versi Protokol	1	Tanggal Versi	13 April 2022
No Versi PSP	1	Tanggal Versi	13 April 2022
Tempat Penelitian	RS Universitas Hasanuddin, RS Dr. Wahidin Sudirohusodo dan RS Grestelina Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 27 April 2022 sampai 27 April 2023	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan